Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some safety/side-effect statements (e.g., muscle pain/myalgia, nausea, fatigue, consulting provider) are directionally consistent with label adverse reactions, but multiple claims are unsupported or inaccurate relative to the provided label excerpts (e.g., muscle weakness/stiffness framing, yoga/repetitive strain/exacerbation, and the 'most common' mapping for trials). No dose/contraindication/warnings content is adequately covered beyond generalities.
Category Scores
Accurate Statements
Lipitor can cause muscle pain.
Label Section 6.1 lists myalgia among the five most common adverse reactions leading to discontinuation.
The most common side effects of Lipitor in clinical trials were nausea.
Label Section 6.1 lists nausea among adverse experiences (within the provided excerpt of common adverse reactions/discontinuation set).
Severe muscle pain, cramping, or weakness while taking Lipitor warrants consulting a healthcare provider.
Label Section 5.1 states that LIPITOR therapy should be temporarily withheld or discontinued in rare rhabdomyolysis/myopathy contexts; consulting a healthcare provider is consistent with seeking medical management for severe muscle symptoms, but the label does not explicitly phrase it as 'warrants consulting.'
A healthcare provider may recommend adjusting Lipitor dosage to alleviate side effects.
Label Section 5.2 recommends reduction of dose or withdrawal of LIPITOR in certain liver enzyme persistence situations; Section 5.1 supports temporarily withholding/discontinuing for skeletal muscle issues. Dose adjustment is not explicitly tied to 'alleviate side effects' in the provided wording, but it is directionally supported for management.
Unsupported Statements
Lipitor can cause muscle weakness.
The provided label excerpts mention myalgia/myopathy and rhabdomyolysis, but 'muscle weakness' is not explicitly listed as a common adverse reaction in the supplied text.
Lipitor can cause muscle stiffness.
Not supported by the provided label excerpts.
Lipitor may affect blood sugar levels.
No blood sugar/glucose/diabetes effects are present in the provided label excerpts.
Lipitor may cause fatigue.
Fatigue is not explicitly present in the provided label adverse reaction excerpts.
Lipitor side effects may be exacerbated by physical activities that involve repetitive strain on muscles, such as yoga.
No activity/exercise/yoga-related exacerbation guidance is present in the provided label excerpts.
The most common side effects of Lipitor in clinical trials were muscle pain.
While myalgia is included as a 'five most common adverse reactions' in the excerpt, 'most common' specifically for 'muscle pain' is not explicitly confirmed as #1; the excerpt does not rank the top single most common.
The most common side effects of Lipitor in clinical trials were fatigue.
Fatigue is not listed in the provided label excerpt for common adverse reactions.
A healthcare provider may provide alternative treatments to alleviate Lipitor side effects.
The label excerpt provided supports withholding/discontinuing LIPITOR and using other lipid-lowering treatments in some contexts, but it does not explicitly say providers may use 'alternative treatments to alleviate Lipitor side effects' in the provided text.
Contradictions
Important Omissions
Specific approved indication(s) and labeled benefits (e.g., reducing MI/stroke/revascularization in specified populations) are not mentioned.
Importance:
High
Label-based contraindications/warnings content (e.g., pregnancy contraindication, breastfeeding not recommended, skeletal muscle/rhabdomyolysis warning framing, and liver test monitoring) is not adequately addressed.
Importance:
High
Administration/dosing details and dose-adjustment/monitoring intervals (e.g., starting dose, titration, lipid checks at 2–4 weeks, pediatric dose limits) are not mentioned.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-related statements are vague or partially supported (muscle symptoms generally supported; weakness/stiffness, fatigue, and yoga-related exacerbation unsupported). Missing major labeled contraindications/monitoring reduces completeness for safe labeling adherence.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple adverse-effect claims (weakness, stiffness, fatigue, blood sugar effects, and exercise/yoga exacerbation) are not supported by the provided label excerpts; indications/major labeled warnings and contraindications are omitted.
Suggested Improvement
Restrict side-effect statements to those explicitly supported in the provided label excerpts (e.g., myalgia; nausea listed among common adverse reactions). Remove unsupported mechanistic/activity-exacerbation claims (e.g., yoga). Add labeled contraindications (pregnancy, breastfeeding) and core warnings/precautions relevant to skeletal muscle and liver monitoring as reflected in the provided sections.